Prana raises $5m from institutional investors

By Melissa Trudinger
Monday, 08 September, 2003

Joining the list of companies taking advantage of increased investor interest in the biotechnology sector, Prana Biotechnology (ASX:PBT) has raised AUD$5 million in a placement to institutional and sophisticated investors at a price of $0.70 per share.

According to CEO Geoffrey Kempler, the placement demonstrates a vote of confidence in the company by investors, and increased understanding of what Prana is trying to achieve.

The funds raised will be used to accelerate the pre-clinical development of the company's lead compound PBT-2 as a therapeutic for Alzheimer's disease. The drug was recently selected from a library of around 300 metal protein attenuating compounds (MPACs) to advance through to clinical trials, and in pre-clinical studies has outperformed PBT-1 (clioquinol), an existing off-label drug that has been successfully tested in proof-of-concept human studies.

"If all goes well, we would like to see Phase I trials start before the end of 2004, probably in the third quarter," said Kempler.

With existing cash, he said, the company had more than $7 million in the bank, enough for at least the next 18 months. Prana also has a milestone-based agreement in place with pharmaceutical company Schering, which will provide $7.3 million in R&D funding plus milestone payments and potentially royalties over the next few years towards new research targets identified by Prana and the development of diagnostics for Alzheimer's disease.

Related News

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Towards safer epilepsy treatment for pregnant women

New research conducted in organoids is expected to provide pregnant women with epilepsy safer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd